TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7872717

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 81
Study: 3061449

Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation
Number of subjects: 0
Study: 31443939

Group type: EXPERIMENTAL
Intervention: Gentamicin-coated intramedullary interlocking nail
Number of subjects: 28

Group type: COMPARATOR
Intervention: Regular intramedullary interlocking nail
Number of subjects: 28
Study: 28711629

Group type: EXPERIMENTAL
Intervention: Standard high-level disinfection (sHLD)
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Double high-level disinfection (dHLD)
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Standard high-level disinfection followed by ethylene oxide gas sterilization (HLD/ETO)
Number of subjects: 541

Group type: COMPARATOR
Intervention: Pre-procedure rectal swabs
Number of subjects: 541

Group type: COMPARATOR
Intervention: Duodenal aspirates
Number of subjects: 541
Study: 25474338

Group type: EXPERIMENTAL
Intervention: Bilateral + Unilateral Plyometric Training (B + UG)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Unilateral Plyometric Training (UG)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Bilateral Plyometric Training (BG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 54
Study: 23921338

Group type: EXPERIMENTAL
Intervention: PRP-augmented treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 48
Study: 19217236

Group type: EXPERIMENTAL
Intervention: Laryngeal tube suction-device (LTS-D)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Endotracheal intubation (ET)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Bag-mask-valve ventilation (BMV)
Number of subjects: 150
Study: 19454547

Group type: EXPERIMENTAL
Intervention: Aprepitant (NK1 receptor antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other NK1 receptor antagonists (under investigation)
Number of subjects: 0
Study: 17096096

Group type: EXPERIMENTAL
Intervention: Bilateral stimulation in the subthalamic nucleus (STN)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (non-operated PD patients)
Number of subjects: 35
Study: 15050851

Group type: EXPERIMENTAL
Intervention: Snoezelen intervention for caregivers
Number of subjects: 6
Study: 15058213

Group type: EXPERIMENTAL
Intervention: Wenshen Xiezhuo Decoction (WSXZD) plus low-protein diets, controlling hypertension, and symptomatic treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-protein diets, controlling hypertension, and symptomatic treatment
Number of subjects: 60
Study: 10194144

Group type: EXPERIMENTAL
Intervention: AHR strategy
Number of subjects: 75

Group type: COMPARATOR
Intervention: reference strategy
Number of subjects: 75
Study: 7538837

Group type: EXPERIMENTAL
Intervention: Amylyte ORS
Number of subjects: 198
Study: 2328561

Group type: EXPERIMENTAL
Intervention: Buprenorphine daily administration (8 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Buprenorphine alternate-day administration
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 19
Study: 38821

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Temazepam 30 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Temazepam 10 mg
Number of subjects: 6
Study: 31281958

Group type: EXPERIMENTAL
Intervention: Lower Hb-threshold for RBC transfusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Higher Hb-threshold for RBC transfusion
Number of subjects: 0
Study: 28042054

Group type: EXPERIMENTAL
Intervention: Tight glycemic control with a blood glucose target range of 80-110 mg/dL (4.4-6.1 mmol/L)
Number of subjects: 1414

Group type: COMPARATOR
Intervention: Standard glycemic control with a blood glucose target range of 150-180 mg/dL (8.3-10.0 mmol/L)
Number of subjects: 1414
Study: 26747421

Group type: EXPERIMENTAL
Intervention: Probiotic milk (150 mL of milk supplemented with Lactobacillus rhamnosus SP1 at 10(7) CFU/mL)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Standard milk
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Probiotic milk
Number of subjects: 261
Study: 24256479

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy with self-hypnosis (7 sessions)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy without self-hypnosis (11 sessions)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups (hypnosis and no-hypnosis)
Number of subjects: 49
Study: 22137119

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 20661199

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA-C)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 40
Study: 17768103

Group type: EXPERIMENTAL
Intervention: Plasma derived C1‐INH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enzyme inhibitor Dx‐88
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Receptor antagonist Icatibant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant form of human C1‐INH
Number of subjects: 0
Study: 15831784

Group type: EXPERIMENTAL
Intervention: Azacitidine administered as a single 75‐mg/m(2) SC dose
Number of subjects: 6

Group type: COMPARATOR
Intervention: Azacitidine administered as a single 75‐mg/m(2) IV infusion dose over 10 minutes
Number of subjects: 6
Study: 11979401

Group type: EXPERIMENTAL
Intervention: Margarine with sterol esters (MSE; 1.92 g/d)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Margarine with stanol esters (MSA; 1.76 g/d)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Margarine (M)
Number of subjects: 15
Study: 9882991

Group type: EXPERIMENTAL
Intervention: Rokitamycin, 400 mg tablet every 12 hours for 14 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Josamycin, 500 mg tablet every 8 hours for 14 days
Number of subjects: 30
Study: 8564679

Group type: EXPERIMENTAL
Intervention: Midazolam (3.4 +/- 1.3 mg)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 31089262

Group type: EXPERIMENTAL
Intervention: Sleep (10% more sleep)
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) (10% more MVPA)
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Compositional time use
Number of subjects: 690
Study: 30002871

Group type: EXPERIMENTAL
Intervention: Effective family planning (EFP) methods (injectable, oral, intra‐uterine contraceptive device, or Norplant)
Number of subjects: 0
Study: 27861326

Group type: EXPERIMENTAL
Intervention: Magnetic resonance-guided laser-induced thermal therapy (MRgLITT)
Number of subjects: 25
Study: 26694646

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS)
Number of subjects: 1391

Group type: COMPARATOR
Intervention: Multiple micronutrient (MMN) supplements
Number of subjects: 1391

Group type: COMPARATOR
Intervention: Iron-folic acid (IFA) supplements
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Perceived stress at 36 wk
Number of subjects: 1391
Study: 22926460

Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Chest Physical Therapy (CPT)
Number of subjects: 24
Study: 20096799

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg od)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 21
Study: 19029420

Group type: EXPERIMENTAL
Intervention: Automated Telephone Symptom Management (ATSM) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive Behavioral Nurse‐Administered Symptom Management intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single agents chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination chemotherapy protocols
Number of subjects: 0
Study: 16497598

Group type: EXPERIMENTAL
Intervention: Nicotine patch + stimulant medication
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nicotine patch only
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo patch + stimulant medication
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo patch only
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nicotine patch administration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 10
Study: 12581463

Group type: EXPERIMENTAL
Intervention: Moderate MUFA (MM) diet
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: High MUFA (HM) diet
Number of subjects: 51

Group type: COMPARATOR
Intervention: Reference (SFA) diet
Number of subjects: 51
Study: 10606836

Group type: EXPERIMENTAL
Intervention: Tolcapone (50, 200 or 400 mg three times daily)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study: 9180124

Group type: EXPERIMENTAL
Intervention: High intensity exercise training (2 h of walking daily and four weekly sessions of high intensity monitored stationary cycling for 2 months)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 25
Study: 1336886

Group type: EXPERIMENTAL
Intervention: 10 mg epinephrine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 2992264

Group type: EXPERIMENTAL
Intervention: Pectin (12 g/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cellulose (15 g/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lignin (12 g/day)
Number of subjects: 30
Study: 29981576

Group type: EXPERIMENTAL
Intervention: Breast pump stimulation (10 min intermittently for each breast with a negative pressure of 250 mmHg)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Oxytocin administration (30 IU in 1000 mL of Ringer's serum, max rate of 10 mL/min)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Breast pump stimulation
Number of subjects: 108

Group type: COMPARATOR
Intervention: Oxytocin administration
Number of subjects: 108
Study: 28812403

Group type: EXPERIMENTAL
Intervention: Text messaging (SMS) once in two weeks
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study: 26612421

Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified rice
Number of subjects: 904

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Children with febrile illness
Number of subjects: 904
Study: 24186591

Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound (QUS) at proximal phalanges using DBM Sonic 1200
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound (QUS) at proximal phalanges
Number of subjects: 55
Study: 21373936

Group type: EXPERIMENTAL
Intervention: Lowering pCO(2) therapy
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Raising pCO(2) therapy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 104
Study: 18786749

Group type: EXPERIMENTAL
Intervention: Early feeding with opioid-sparing analgesia
Number of subjects: 62

Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 62
Study: 16644317

Group type: EXPERIMENTAL
Intervention: Intensive periodontal therapy (IPT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard periodontal therapy
Number of subjects: 40
Study: 12809583

Group type: EXPERIMENTAL
Intervention: Isoniazid 300 mg once daily (Group 1)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Isoniazid 900 mg/twice weekly (Group 2)
Number of subjects: 37
Study: 10852265

Group type: EXPERIMENTAL
Intervention: Thalidomide (initially 100 mg daily, reduced to 50-25 mg daily for maintenance)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 22
Study: 8856544

Group type: EXPERIMENTAL
Intervention: Biodegradable pins
Number of subjects: 23

Group type: COMPARATOR
Intervention: Kirschner wires
Number of subjects: 23
Study: 1739629

Group type: COMPARATOR
Intervention: Carboplatin 400 mg m‐2 alone (Arm A)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Carboplatin 300 mg m‐2 with chlorambucil 10 mg day‐1 for 7 days (Arm B)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Both arms (A and B)
Number of subjects: 161
Study: 6748722

Group type: EXPERIMENTAL
Intervention: Reperfusion solution (1 L delivered just prior to removal of the aortic clamp)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (unmodified blood reperfusate)
Number of subjects: 112
Study: 29572190

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27050843

Group type: EXPERIMENTAL
Intervention: 6-step hand hygiene technique
Number of subjects: 120

Group type: COMPARATOR
Intervention: 3-step hand hygiene technique
Number of subjects: 120
Study: 23662599

Group type: EXPERIMENTAL
Intervention: Firocoxib chewable preparation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Firocoxib equine paste
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 18
Study: 23088336

Group type: EXPERIMENTAL
Intervention: Once-daily darunavir/ritonavir (DRV/r) 800/100 mg
Number of subjects: 689

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r) 800/200 mg
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: Once-daily darunavir/ritonavir (DRV/r)
Number of subjects: 689

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 689
Study: 20561645

Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (InterStim)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 33
Study: 18212487

Group type: EXPERIMENTAL
Intervention: Urinary NTX measurements
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Serum NTX measurements
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 16391473

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors (specific drugs not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors
Number of subjects: 0
Study: 15288412

Group type: EXPERIMENTAL
Intervention: i.v. fentanyl plus low dose i.v. ketamine (group 1)
Number of subjects: 143

Group type: COMPARATOR
Intervention: i.v. fentanyl (group 2)
Number of subjects: 143

Group type: COMPARATOR
Intervention: i.v. fentanyl (group 3)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Pre-operative low-dose i.v. ketamine (group 1)
Number of subjects: 143
Study: 11407694

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 71
Study: 9248867

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 40
Study: 7969342

Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (40 micrograms subcutaneously daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nafarelin (200 micrograms intranasally twice daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nafarelin plus parathyroid hormone
Number of subjects: 40
Study: 3311550

Group type: EXPERIMENTAL
Intervention: Bay‐m‐1099 (50 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 29112939

Group type: EXPERIMENTAL
Intervention: Serious games platform (Rehab@Home)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Exergame using the Wii platform
Number of subjects: 16
Study: 27060152

Group type: EXPERIMENTAL
Intervention: DDGP (dexamethasone, cisplatin, gemcitabine, and pegaspargase)
Number of subjects: 42

Group type: COMPARATOR
Intervention: SMILE (dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide)
Number of subjects: 42
Study: 24452700

Group type: EXPERIMENTAL
Intervention: External focus (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Internal focus (n = 10)
Number of subjects: 20
Study: 22246378

Group type: EXPERIMENTAL
Intervention: Moderate and vigorous exercise training for 12 weeks
Number of subjects: 29
Study: 20630306

Group type: EXPERIMENTAL
Intervention: NaOCl solution
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NaOCl gel
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40
Study: 18362558

Group type: EXPERIMENTAL
Intervention: EMLA cream application
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 15919434

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) and tacrolimus (TAC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Prednisone (PRED) and tacrolimus (TAC)
Number of subjects: 30
Study: 12564350

Group type: EXPERIMENTAL
Intervention: Massage Therapy (MT)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (TT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Friendly Visit (FV)
Number of subjects: 88
Study: 10555246

Group type: EXPERIMENTAL
Intervention: Experimental group (interviewed about attitudes towards pain)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Type II attitudes (focusing on pain sensation)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Type I attitudes (focusing on disorder)
Number of subjects: 26
Study: 8909331

Group type: EXPERIMENTAL
Intervention: Nadolol 120 mg/day
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 1907599

Group type: EXPERIMENTAL
Intervention: Caregiver Support Program (CSP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional community nursing care
Number of subjects: 0
Study: 6683399

Group type: EXPERIMENTAL
Intervention: Extracontact procedures (baby placed on mother's abdomen for 1 hour)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Routine care procedures (baby shown to mother and then taken to nursery)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Extracontact procedures
Number of subjects: 59

Group type: COMPARATOR
Intervention: Both extracontact and routine care procedures
Number of subjects: 59
Study: 30855442

Group type: EXPERIMENTAL
Intervention: Sequential acupoint stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine nursing
Number of subjects: 0
Study: 29741592

Group type: EXPERIMENTAL
Intervention: SAFE (surgery, antibiotics, facial cleanliness, and environmental improvement) interventions
Number of subjects: 15632

Group type: EXPERIMENTAL
Intervention: Chlamydial infection
Number of subjects: 15632
Study: 26762729

Group type: EXPERIMENTAL
Intervention: APSES (MiStent)
Number of subjects: 805

Group type: COMPARATOR
Intervention: EES (Xience)
Number of subjects: 805
Study: 25682077

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg daily for 1 week then 1 g twice daily for a further week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not receiving metformin)
Number of subjects: 0
Study: 22257314

Group type: EXPERIMENTAL
Intervention: Freshest available blood
Number of subjects: 910

Group type: COMPARATOR
Intervention: Standard-age blood
Number of subjects: 910
Study: 20975299

Group type: EXPERIMENTAL
Intervention: Acute exercise bout
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 4 weeks of physical training without antioxidants
Number of subjects: 80

Group type: COMPARATOR
Intervention: 4 weeks of physical training with antioxidants (vitamin C 1,000 mg/day and vitamin E 400 IU/day)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 1-hour exercise bout
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 4 weeks of training
Number of subjects: 80
Study: 18846024

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg, single dose)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 15957827

Group type: EXPERIMENTAL
Intervention: Compound periploca liquid (CPL)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Periploca syrup
Number of subjects: 81

Group type: COMPARATOR
Intervention: Youtuoxin (YXG)
Number of subjects: 81
Study: 12143978

Group type: EXPERIMENTAL
Intervention: Comminution of the femoral calcar
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Varus displacement in excess of 30 degrees
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Small head fragment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Garden classification (overall)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Garden classification (divided into Garden 1‐2 and 3‐4)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Displaced vs. undisplaced classification
Number of subjects: 32
Study: 10513491

Group type: EXPERIMENTAL
Intervention: 8-week weight-bearing physical conditioning program
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control period (8 weeks before exercise)
Number of subjects: 25
Study: 7781839

Group type: EXPERIMENTAL
Intervention: Nutri-Expert
Number of subjects: 155
Study: 2031815

Group type: EXPERIMENTAL
Intervention: Atracurium 0.2 mg kg‐1 with previous suxamethonium 1 mg kg‐1
Number of subjects: 18

Group type: COMPARATOR
Intervention: Atracurium 0.2 mg kg‐1 without previous suxamethonium
Number of subjects: 18
Study: 6382991

Group type: EXPERIMENTAL
Intervention: Propranolol (40 to 240 mg twice a day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Verapamil (120 to 240 mg twice a day)
Number of subjects: 19
Study: 30202883

Group type: EXPERIMENTAL
Intervention: Vuse Solo (VS) Digital Vapor Cigarettes
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Nicorette 4 mg nicotine gum (NG)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Combustible cigarettes (CCs)
Number of subjects: 153
Study: 29449034

Group type: EXPERIMENTAL
Intervention: Horticultural activities
Number of subjects: 11

Group type: COMPARATOR
Intervention: Occupational activities
Number of subjects: 11
Study: 27549415

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 136

Group type: COMPARATOR
Intervention: Transcervical Foley catheter plus oxytocin
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Higher parity and higher Bishop's score
Number of subjects: 136
Study: 24727719

Group type: EXPERIMENTAL
Intervention: Self-disclosure comedy sketch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nondisclosure comedy sketch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control comedy sketch
Number of subjects: 0
Study: 22871173

Group type: EXPERIMENTAL
Intervention: Diet, physical exercise and cognitive behavioral training during working hours 1 hour/week
Number of subjects: 98

Group type: COMPARATOR
Intervention: Monthly oral presentations
Number of subjects: 98